Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher A Carter

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
American Journal of Public Health|December 21, 2023
The Resignation on RaceChristopher A Carter
International Journal of Cancer|December 21, 2010
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityScott M Wilhelm, Jacques Dumas, Lila Adnane, et al.
Cancer Chemotherapy and Pharmacology|May 26, 2006
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinomaChristopher A Carter, Charles Chen, Cheryl Brink, et al.
Oncogene|July 12, 2005
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006Chunrong Yu, Laura M Bruzek, Xue Wei Meng, et al.
Molecular Cancer Therapeutics|September 21, 2006
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathwaysChunrong Yu, Bret B Friday, Jin-Ping Lai, et al.
Cancer Chemotherapy and Pharmacology|December 13, 2006
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft modelsYong S Chang, Jalila Adnane, Pamela A Trail, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
American Journal of Public Health|December 21, 2023
The Resignation on RaceChristopher A Carter
International Journal of Cancer|December 21, 2010
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityScott M Wilhelm, Jacques Dumas, Lila Adnane, et al.
Cancer Chemotherapy and Pharmacology|May 26, 2006
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinomaChristopher A Carter, Charles Chen, Cheryl Brink, et al.
Oncogene|July 12, 2005
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006Chunrong Yu, Laura M Bruzek, Xue Wei Meng, et al.
Molecular Cancer Therapeutics|September 21, 2006
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathwaysChunrong Yu, Bret B Friday, Jin-Ping Lai, et al.
Cancer Chemotherapy and Pharmacology|December 13, 2006
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft modelsYong S Chang, Jalila Adnane, Pamela A Trail, et al.
Pageof 1